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Abstract: Molecular chaperones and the heat shock response play a major role in the maintenance of cellular homeostasis under various 
pathological conditions. In particular, their role is to regulate protein conformation, protect proteins from misfolding and aggregation, and 
maintain signalling and organellarnetworks. Among variousheat shock proteins, Hsp32 also known as heme oxygenase-1 (HO-1), has 
demonstrated an important role in metabolic syndrome. In particular, the HO system seems to play a major role in the complex patho-
physiological cascade involved in insulin resistance mechanisms, and adipocyte functions as measured by the release of important adipo-
kynes. The aim of the present review is to point out the role of HO-1 in metabolic syndrome, and how to exploit its beneficial effects as a 
therapeutic strategy to prevent complicationsof andto improve insulin sensitivity. 
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INTRODUCTION 
 The prevalence of obesity, sedentary lifestyle, and the ageing of 
the population is on the rise globally [1], leading to an increased 
risk of cardiovascular disease and type 2 diabetes. The metabolic 
syndrome represents a clustering of pathologic factors including 
central obesity, glucose intolerance, hypertension, and dyslipide-
mia, with the underlying common thread of insulin resistance. Sev-
eral expert groups have suggested in the last few years diagnostic 
criteria to be used in clinical practice to identify patients with meta-
bolic syndrome, and these definitions have been somewhat different 
[2]. 
 As stated by the joint American Heart Association/National 
Heart, Lung, and Blood Institute Scientific Statement on “Diagnosis 
and Management of the Metabolic Syndrome” III [3], all the pro-
posed classifications have in common the concept that the meta-
bolic syndrome represents a constellation of interrelated risk factors 
of metabolic origin (“metabolic risk factors”) that appear to directly 
promote the development of atherosclerotic cardiovascular disease. 
The metabolic risk factors include elevated blood pressure, elevated 
plasma glucose, and atherogenic dyslipidemia, which consists of an 
aggregation of lipoprotein abnormalities including elevated plasma 
triglyceride levels, increased small, dense low-density-lipoproteins 
(LDL), and reduced high-density-lipoproteins (HDL)-cholesterol 
concentrations [4]. 
 The pathophysiology of the metabolic syndrome results from a 
complex genetic and environmental interaction, contributing to 
atherosclerosis and increasing the risk of glucose intolerance and 
diabetes [5, 6] through a process of chronic and incremental dam-
age to the arterial wall. The mechanisms underlying atherosclerosis 
are incompletely understood. In addition to the aforementioned risk 
factors, a number of other processes including hypercoagulability, 
oxidative stress, endothelial dysfunction, chronic infection, and 
inflammation have been proposed. 
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 Recent studies have also suggested the role of heat-shock pro-
teins (HSP)s in cardio-metabolic risk [7-10].The Aim of this review 
article is to discuss the role of HSPs in the metabolic syndrome and 
its associated cardiovascular risks. 
HEAT SHOCK PROTEINS, MOLECULAR CHAPERONES 
AND CHAPERONOPATHIES 
 Heat shock proteins (Hsps) are ubiquitous proteins, highly con-
served during evolution that are involved in many vital functions 
such as gene expression regulation, cell differentiation, DNA repli-
cation, signal transduction, programmed apoptosis, cellular senes-
cence and immortalization [11-13]. Since there are several groups 
of Hsps, a classification of practical value in research and practice 
is that based on molecular weight (Table 1).  
 Many members of the Hsp families are present constitutively in 
cells while some are expressed only after stress [11, 14]. Several 
mechanisms exist to regulate the abundance of cytosolic and nu-
clear chaperones, and activation of heat shock transcription factor 1 
(HSF1) is an essential aspect of the heat shock response. In higher 
eukaryotes, triggering of the heat-shock response is mediated by 
this master regulator, HSF1 [11, 15]. The activated HSF enters the 
nucleus and binds to heat-shock elements (HSE) in the promoter 
region of the selected Hsp gene [11]. Inthe absence of stressors, 
Hsp-chaperones have multiple housekeeping functions, such as 
folding and translocation of newly synthesized proteins, protein 
degradation, and activation of transcription factors, and they also 
participate in determining tumour immunogenicity and antigenic 
presentation [11, 13, 16]. 
 Many Hsps are molecular chaperones, and here we will use the 
terms, Hsp and molecular chaperone, interchangeably. Molecular 
chaperones assist in protein folding, degradation, and intracellular 
trafficking [11, 12, 17]. As a consequence, aberrant expression of 
chaperone genes may cause various disorders. A group of patholo-
gies, due to congenital or acquired malfunction of chaperones, has 
been described as chaperonopathies [12, 17-19]. The number of 
papers demonstrating a link between Hsps dysfunction and meta-
bolic syndrome is growing [20-22], and hence this syndrome is 
expected to be included soon among chaperonopathies. 
2   Current Pharmaceutical Design, 2014, Vol. 20, No. 00 Barbagallo et al. 
 However, an important issue is that many other Hsps are not 
chaperones (and vice versa). Unfortunately, these distinctions have 
not been made in the great majority of published work on these 
molecules that use the names Hsp and chaperones interchangeably. 
Hsp32, also named Heme-oxygenase-1 (HO-1), is one of the most 
important Hsp’s without achaperoning function. HO-1 is the induc-
ible isoform of heme oxygenase, which catalyzes the NADPH, O2 
and cytochrome P450 reductase dependent oxidation of heme to 
carbon monoxide, iron and biliverdin that is immediately reduced to 
bilirubin [23, 24]. another inducible protein by heat shock is Heme 
Oxygenase –1 (HO-1), and therefore has also been referred to as 
heat shock protein (hsp) 32 [25]. Heme oxygenase 1 or heat shock 
protein 32 is a member ofthe heme oxygenase (HO) protein family. 
Heme oxygenase (HO) catalyzes the rate-limiting step in heme 
degradation, yielding biliverdin IX [alpha], iron, and carbon mon-
oxide (CO) . The HO enzyme system comprises two isoenzymes, 
namely HO-1 and HO-2, which are encoded by distinct genes. Al-
though HO-2 appear to be constitutively expressed, HO-1 is highly 
inducible under a variety of conditions associated with oxidative 
stress, i.e., glutathione depletion [26], ischemia/reperfusion [27], 
hyperoxia [28], hypoxia [29], endotoxemia [30], in cell lines de-
rived from a variety of species. The heme–heme oxygenase (HO) 
system serves as an important cellular antioxidant defense system in 
obesity, diabetes and generally ina metabolic syndrome.  
 Another important issue is that researchhas recently shown 
various ways by which cells are able to actively secrete Hsps, i.e., 
using the classic Golgi’s or the alternative lipid rafts-exosome 
pathways [16, 31-33]. 
HEME OXYGENASE 1 AND METABOLIC SYNDROME 
 Oxidative stress has long been implicated in the pathogenicity 
of insulin resistance in Type 2 Diabetes and of with cardiovascular 
complications [34]. Oxidative stress is one of the underlying 
mechanisms in the pathogenesis of hyperglycemia-inducedtissue 
damage,  cell dysfunction, and endothelial dysfunction. Hypergly-
cemia increases O2

 production, culminating in oxidative tissue 
damage within multiple organ systems, and chronic oxidative stress 
has also been linked to glucose toxicity and cellular destruction of  
cells in Type 2 Diabetes [35]. 
 Thus, it is not surprising that HO-1, as a Key antioxidant en-
zyme, has consistently been shown to protect against the develop-
ment of diabetes [36]. 
 The mechanisms by which HO-1has mediated these effects are 
various, and besides its antioxidant action, HO-1 also directly af-
fects glucose metabolism, which might be due to the presence of a 
binding site for a glucocorticoid-responsive element in the HO-1 
gene promoter [37]. In fact, HO-1 was shown to stimulate insulin 
production in experimental animal models [36], at least partially, 
via the release of carbon monoxide [38], which is an immediate 
product of HO-1. Indeed, HO-1 induction by hemin has been dem-
onstrated to improve insulin signaling and glucose metabolism, and 
to have lowered insulin resistance in various animal models, includ-
ing streptozotocin-induced diabetes[39], insulin-resistant type 2 
diabetes [40], as well as essential hypertension[41]. 
 Besides improving insulin sensitivity, HO-1 induction has been 
reported to reduce visceral and subcutaneous obesity in diabetic and 
obese mice [42, 43] through mechanisms involving the attenuation 
of the inflammatory processes, as well as modulation of PPAR 
signaling [44]. Furthermore, chronic HO-1 induction has been 
shown to increase metabolic turnover, heat production, and physical 
activity in an experimental model of obesity [45], suggesting the 
complexityofthebeneficialeffectsofHO-1inductionuponthese meta-
bolic disorders. 
 Early studies demonstrated thata decrease in HO-1 gene expres-
sion observed with hyperglycemia in experimental diabetes was 
associated with an increase of endothelial cells into the circulation, 
presumably reflecting cell damage and an elevation of oxidant pro-
duction in vivo. These findings were reversed bya human HO-1 
gene transfer, suggesting that heme-HO-1 system appears to be 
significantly involved in vascular endothelial cell physiology [46, 
47]. 
 Ndisang and colleagues showed that up-regulation of the heme 
oxygenase system with hemin improves insulin sensitivity and glu-
cose metabolisms pontaneously in adult Hypertensive Rats (SHRs) 
[48], representing a model of essential hypertension with character-
istics ofa metabolic syndrome. In particular, the authors showed 
that hemin treatment enhanced the antioxidant status in SHRs, and 
reduced oxidative stress by an increment of bilirubin, ferritin, SOD, 
and catalase, and reverted proinflammatory/oxidative transcription 
factors as AP-1, AP-2, NF-kB, and JNK. Moreover, elevated oxida-
tive stress depletes insulin levels [49] and activates JNK, causing 
insulin resistance [49, 50], whereas the suppression of JNK leads to 
improved glucose tolerance for the increased insulin production in 
SHRs. 
 Furthermore, Abraham et al. demonstrated that upregulation of 
HO-1, in association with increased levels of adiponectin 
,prevented vascular and cardiac dysfunction in SHRs fed a high fat 
diet, a phenotype designed to mimica metabolic syndrome. In par-
Table 1. Subpopulations of Hsp-chaperones.  
NAME OTHER NAMES MW (kDa) 
Super-Heavy Sacsin 200 or higher 
Heavy High  Hsp100 100–199 
Hsp90 HSP86; HSP89A; HSP90A; HSP90N; HSPC1; HSPCA; LAP2; FLJ31884 81–99 
Hsp70 Chaperones; DnaK 65–80 
Hsp60 Chaperonins (Groups I and II); Cpn60 and CCT 55–64 
Hsp40 DnaJ 35–54 
Small Hsp sHsp; alpha-crystallins; Hsp10 34 or less 
Other Proteases;  isomerases; AAA + proteins (e.g., paraplegin [SPG7]; spastin [SPG4]; torsin A); Alpha Hemoglobin-
Stabilizing Protein (AHSP); clusterin; PPI (cyclophilin); etc 
Various 
Hsp32 Heme oxygenase-1 32 
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ticular, the authors have shown that the inhibition of HO activity 
prevented the beneficial effects of HO-1 induction in obese SHR 
with regard to blood pressure, adiponectin, pAKT and pAMPK 
[51]. These data support the beneficial role of pharmaco-genetic 
interventions targeted towards HO-1-adiponectin axis in patients 
with metabolic syndrome. Such patients often exhibit chronic en-
ergy imbalance, along with a wide array of cardiovascular abnor-
malities amenable to aggravation by confounding factors such as 
diet induced obesity. Restoration of metabolic homeostasis by acti-
vationof the HO-1-adiponectin axis could not only improve the 
energy profile, but also attenuate associated cardiovascular patho-
physiological alterations observed in patients withmetabolic syn-
drome.  
 On the other hand, adipose tissue dysfunction has been shown 
to be a mediator in the development of obesity-associated complica-
tions and metabolic syndrome [52]. Several studies have demon-
strated that HO-1 induction improves insulin sensitivity, reduces 
adipose tissue volume and causes adipose tissue remodeling in a 
model of obesity-induced insulin resistance, suggesting that HO-1 
could be used as potential therapeutic target for obesity and its as-
sociated health risks [53]. In addition, it has been demonstrated that 
HO-1 expression increases mesenchymal stem cell-derived os-
teoblasts, but decreases adipocyte lineage [54, 55] suggesting that 
targeting HO-1 gene expression attenuates the hyperglycemia-
mediated decrease in MSC-derived osteoblast differentiation [56]. 
 The deregulated expression of adipokines and inflammatory 
cytokines by adipocytes and infiltrating macrophages in adipose 
tissue contributes to obesity-induced insulin resistance [57, 58]. 
Several chemotactic factors, including monocytic chemotactic pro-
tein-1 (MCP-1), osteopontin, CXC motif chemokine ligand-14, and 
angiopoietin-like protein 2, are upregulated in adipose tissue during 
the early phase of obesity, and mediating the recruitment of mono-
cytes to adipose tissue, andthe genetic ablation of these genes ame-
liorates obesity-induced adipose inflammation and insulin resis-
tance in animals [59-62]. These findings emphasize the significance 
of adipose macrophage infiltration in the development of theobe-
sity-associated metabolic syndrome. Recent studies[63]have identi-
fied a novel function of HO-1 in macrophages. Although it is re-
garded as an anti-inflammatory enzyme which suppresses the pro-
duction of proinflammatory cytokines in macrophages, HO-1 can 
impact the migration response of macrophages through modulating 
p38 and FAK activations. HO-1 expression in hematopoietic cells 
promotes the migration of macrophages toward the adipose tissue 
during obesity, and exacerbates the development of metabolic dis-
ease. This finding is contradictory to the other reports showing that 
systemic induction of HO-1 in diabetic animals reduced adiposity 
and improved insulin sensitivity [43, 64]. In this regard, the salutary 
effects of HO-1 on adipocytes and skeletal muscles as demonstrated 
in these studies might overpower the effect of HO-1 on macrophage 
migration toward obese adipose tissue, and the down-regulation of 
chemokine expression induced by HO-1 in adipocytes might restrict 
the adipose macrophages recruitment . 
 Furthermore, it has beendemonstrated that HO-2 deletion leads 
to manifestations of the metabolic syndrome, including obesity, 
hypertension, and insulin resistance. These changes in the HO-2-
null mouse were associated with impaired vascular function, in-
creased inflammatory signals, and alterations in cytoprotective 
circuits, including HO-1, epoxygenase-derived EETs, and adi-
ponectin [65]. In this study, the first cytoprotective circuit that was 
altered by HO-2 deletion was the HO system. The authors showed 
that HO-2 deletion leads to reduced HO-1 expression and a de-
crease in HO activity.HO-2 deficiency enhanced diabetes-induced 
renal dysfunction and morphologic injury, and HO-1 up-regulation 
in the HO-2-null mouse rescued and prevented the morphologic 
damage [66]. HO-2 is critical for HO-1 expression andto illustrate 
the fact that the subsequent failure to up-regulate the HO system 
may contribute to unresolved inflammation, and the development of 
chronic inflammatory conditions [67]. HO-1 induction or overex-
pression abrogates the injurious consequences of obesity and hyper-
tension, whereas inhibition of HO activity exacerbates these condi-
tions [68]. Therefore, it is notsurprising that HO-2-null mice exhib-
ited similar characteristics as obmice in which the HO-1 suppres-
sion displays metabolic syndrome [64, 69]. Furthermore, the dimin-
ished activity of the HO system in metabolic syndrome may con-
tribute to increased oxidative stress and inflammatory conditions, 
and consequently to derangements in the regulation of adipogene-
sis, increased blood pressure. Finally, Vanella L. et al showed that 
HO-2 plays a major role in adiponectin release by a protein-protein 
interaction mechanisms thus further suggesting that the HO system 
may serve as chaperone proteins (LUCA BBRC 2013).  
CONCLUSIONS AND FUTURE PERSPECTIVES 
 HO-1 plays an important role in contributing to metabolic con-
trol in in vitro and in vivo models. These results were also con-
firmed in human research suggesting that HO-1 may serve as a 
potential target for metabolic control and metabolic syndrome-
related complications. Finally, future studies are now warranted in 
order to fully elucidate how to exploit HO-1 byproducts for their 
beneficial and therapeutic effects in themetabolic syndrome. 
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